Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.
GS-1811 is designed to selectively deplete immune system-suppressing T regulatory cells that infiltrate the area in and around tumors, giving the body's immune system a better chance at fighting off the cancer. "GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment works from inside cancerous cells to shrink solid tumors," said Dr.Richard Murray
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: